Drug Patents Expiring in 2043
1. Auvelity patent expiration
Can you believe AUVELITY received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11925636 | AXSOME | Bupropion dosage forms with reduced food and alcohol dosing effects |
Jan, 2043
(18 years from now) | |
| US11717518 | AXSOME | Bupropion dosage forms with reduced food and alcohol dosing effects |
Jan, 2043
(18 years from now) | |
| US11730706 | AXSOME | Treatment of depression in certain patient populations |
Jan, 2043
(18 years from now) | |
| US11883373 | AXSOME | Treatment of depression in certain patient populations |
Jan, 2043
(18 years from now) | |
| US12036191 | AXSOME | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
Feb, 2043
(18 years from now) | |
| US11986444 | AXSOME | Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan |
Feb, 2043
(18 years from now) | |
| US12042473 | AXSOME | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Feb, 2043
(18 years from now) | |
| US11752144 | AXSOME | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Feb, 2043
(18 years from now) | |
| US11839612 | AXSOME | Compounds and combinations thereof for treating neurological and psychiatric conditions |
Mar, 2043
(18 years from now) | |
| US11844797 | AXSOME | Combination of dextromethorphan and bupropion for treating depression |
Apr, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 18, 2025 |
Drugs and Companies using BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE ingredient
Market Authorisation Date: 18 August, 2022
Treatment: Dextromethorphan and bupropion in combination to treat major depressive disorder; Treatment of major depressive disorder by administering dextromethorphan and bupropion to a subject having moderate he...
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of AUVELITY before it's drug patent expiration?
More Information on Dosage
AUVELITY family patents
2. Brukinsa patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11911386 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(18 years from now) | |
| US11896596 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(18 years from now) | |
| US11786531 | BEIGENE | Methods of treating B-cell proliferative disorder |
Jan, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-871) | Aug 31, 2024 |
| New Indication(I-874) | Sep 14, 2024 |
| New Chemical Entity Exclusivity(NCE) | Nov 14, 2024 |
| New Indication(I-817) | Jan 19, 2026 |
| Orphan Drug Exclusivity(ODE-276) | Nov 14, 2026 |
| New Indication(I-936) | Mar 07, 2027 |
| Orphan Drug Exclusivity(ODE-371) | Aug 31, 2028 |
| Orphan Drug Exclusivity(ODE-370) | Sep 14, 2028 |
| Orphan Drug Exclusivity(ODE-274) | Jan 19, 2030 |
| Orphan Drug Exclusivity(ODE-467) | Mar 07, 2031 |
Drugs and Companies using ZANUBRUTINIB ingredient
NCE-1 date: 15 November, 2023
Market Authorisation Date: 14 November, 2019
Treatment: Treatment of adult patients with relapsed or refractory follicular lymphoma (fl) receiving a moderate cyp3a inducer, in combination with obinutuzumab, after two or more lines of systemic therapy; Trea...
Dosage: CAPSULE
More Information on Dosage
BRUKINSA family patents
3. Exparel patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11918565 | PACIRA PHARMS INC | Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions |
Feb, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 28, 2014 |
| New Indication(I-771) | Apr 06, 2021 |
| New Patient Population(NPP) | Mar 22, 2024 |
| New Indication(I-929) | Nov 09, 2026 |
Drugs and Companies using BUPIVACAINE ingredient
Market Authorisation Date: 28 October, 2011
Treatment: A method of administering bupivacaine to produce regional analgesia via sciatic nerve block in the popliteal fossa in adults
Dosage: INJECTABLE, LIPOSOMAL
How can I launch a generic of EXPAREL before it's drug patent expiration?
More Information on Dosage
EXPAREL family patents
4. Igalmi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11998528 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(18 years from now) | |
| US12090140 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(18 years from now) | |
| US11806334 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Apr 05, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual or buccal administration; A method of treating agitation associated with schizophrenia or bipolar i...
Dosage: FILM
More Information on Dosage
IGALMI family patents
5. Ogsiveo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11951096 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11938116 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11925620 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11925619 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US12011434 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US12036207 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11872211 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US12011435 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| US11957662 | SPRINGWORKS | Treatments with nirogacestat |
May, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 27, 2028 |
| ODE*(ODE*) | Nov 27, 2030 |
| Orphan Drug Exclusivity(ODE-452) | Nov 27, 2030 |
Drugs and Companies using NIROGACESTAT HYDROBROMIDE ingredient
NCE-1 date: 28 November, 2027
Market Authorisation Date: 27 November, 2023
Treatment: Treatment of adult patients with progressing desmoid tumors
Dosage: TABLET
More Information on Dosage
OGSIVEO family patents
6. Purified Cortrophin Gel patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11975047 | ANI PHARMS | Methods for storing and warming purified corticotropin compositions |
Oct, 2043
(18 years from now) | |
| US12102662 | ANI PHARMS | Methods for storing and warming purified corticotropin compositions |
Oct, 2043
(18 years from now) | |
Drugs and Companies using CORTICOTROPIN ingredient
Market Authorisation Date: 01 January, 1982
Treatment: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; During an exacerbation or as maintenance therapy ...
Dosage: INJECTABLE
More Information on Dosage
PURIFIED CORTROPHIN GEL family patents
7. Tarpeyo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11896719 | CALLIDITAS | Pharmaceutical compositions |
Jan, 2043
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 15, 2024 |
| Orphan Drug Exclusivity(ODE-389) | Dec 15, 2028 |
| Orphan Drug Exclusivity(ODE-464) | Dec 20, 2030 |
Drugs and Companies using BUDESONIDE ingredient
Market Authorisation Date: 15 December, 2021
Treatment: Reduction in loss of kidney function and reduction of proteinuria in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression, by release of budesonide from the f...
Dosage: CAPSULE, DELAYED RELEASE
More Information on Dosage
TARPEYO family patents
List of large molecules
1. List of Xolair large molecules
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| US12030959 | GENENTECH, INC. | Anti-IgE antibody therapy for multiple food allergies |
Jul, 2043
(18 years from now) |
Ingredients: OMALIZUMAB